IGF-1 Blood Test: Normal Ranges & Causes | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

IGF-1 blood test

Insulin-like growth factor 1. Also called: IGF-I, Somatomedin C, Sm-C

Biomarker guideLast updated: October 29, 2026

IGF-1 is the blood test doctors use to check growth hormone activity. Normal ranges depend on age, sex and the lab's assay. Several peptides raise it, a few lower it, and some popular ones did not change it in trials.

LOINC 2484-4Hormones

At a glance

What it measuresIGF-1, the hormone that carries out much of growth hormone's effect on growth. Most of it is made in the liver.
SampleBlood (serum). Neither Labcorp nor Mayo lists fasting.
Typical adult rangeDepends on age, sex and lab. Labcorp, ages 41-45: men 84-270 ng/mL, women 74-239 ng/mL.
Peptides that move itRaised by MK-677 (Ibutamoren), CJC-1295, Tesamorelin and others. Lowered by somatostatin analogs such as Octreotide. Hexarelin did not change it in a 16-week trial.
Lab codeLOINC 2484-4 (Labcorp 010363, Mayo FIGF1)

What is IGF-1?

IGF-1 (insulin-like growth factor 1) is a 70-amino-acid hormone with a structure similar to proinsulin. Growth hormone tells the liver to make it, and the liver is the main source of the IGF-1 in your blood.

Labs measure it to look for growth hormone excess or deficiency, to monitor growth hormone and IGF-1 treatment, and in conditions that cause poor nutrition or muscle wasting. Older lab reports and papers call it somatomedin C.

Sources: [1] [2] [3]

How it is made and regulated

Where it is made

In mice whose liver cells could not make IGF-1, blood IGF-1 fell by 75%, even though the liver is less than 5% of body mass. A second knockout study found the same large drop. In two healthy adults, total IGF-I production was estimated at about 10 mg per day.

Sources: [2] [4] [5]

What controls it

Growth hormone switches IGF-1 on: in rat liver, GH recruited the transcription factor STAT5b to 15 binding sites around the IGF-1 gene. Insulin arriving from the gut through the portal vein also matters, because it sets how sensitive the liver is to growth hormone. IGF-1 in turn feeds back to reduce growth hormone release.

Sources: [6] [7]

How it travels in the blood

Almost none of it circulates free. More than 80% is held in a three-part complex with IGF binding protein 3 (IGFBP-3) and a protein called the acid-labile subunit. That complex keeps IGF-1 in the blood much longer.

Sources: [8] [9]

How long it lasts

In tracer studies in two healthy adults, free IGF-I lasted 10-12 minutes, IGF-I in smaller 50-kD complexes lasted 20-30 minutes, and IGF-I in the large 200-kD complex lasted 12-15 hours.

Sources: [5]

What it does

IGF-1 drives bone growth at the growth plates, makes cells divide, and lowers blood sugar by cutting the liver's glucose output and helping tissues take up glucose. Labcorp describes it as the major effector of GH-stimulated growth.

Sources: [8] [3]

Reference ranges

Each lab sets its own ranges for its own assay, so the two tables below do not match. Use the range printed on your report.

Labcorp (test 010363)

Method: Immunochemiluminometric assay (ICMA), IDS-iSYS, calibrated to the WHO standard 02/254. Labcorp test page (retrieved October 29, 2026).

Adults

Age (years)Male (ng/mL)Female (ng/mL)
18145-506117-430
19122-435113-408
20116-410108-384
21-25109-353101-347
26-30101-30791-308
31-3595-29084-281
36-4090-27879-259
41-4584-27074-239
46-5081-26370-225
51-5574-25565-216
56-6068-24760-207
61-6564-24057-202
66-7059-23052-196
71-7553-22248-191
76-8045-20742-185
81-8540-19439-177
86-9033-17634-169
>90Not establishedNot established
Children and teens
Age (years)Male (ng/mL)Female (ng/mL)
<118-7914-106
120-10823-136
224-13530-163
328-14834-192
432-16538-217
537-19646-243
643-22956-268
750-24364-288
859-27574-337
967-31581-405
1075-36685-526
1182-42391-610
1287-519110-656
13101-620150-678
14123-701174-656
15161-760156-586
16171-748140-517
17161-635130-471

Labcorp built these intervals from a US routine-testing population of 778,173 males and 710,752 females aged 0-90. No range is set above 90.

Mayo Clinic Laboratories (performed by Quest Diagnostics, LC/MS) (test FIGF1)

Method: Liquid chromatography mass spectrometry (LC/MS), performed by Quest Diagnostics Nichols Institute. Mayo Clinic Laboratories (performed by Quest Diagnostics, LC/MS) test page (retrieved October 29, 2026).

Adults

Age (years)Male and female (ng/mL)
18-19108-548
20-2483-456
25-2963-373
30-3953-331
40-4952-328
50-5950-317
60-6941-279
70-7934-245
>8034-246
Children and teens
Age (years)Male (ng/mL)Female (ng/mL)
<114-14217-185
112-13415-175
212-13516-179
330-15538-214
428-18134-238
531-21437-272
638-25345-316
748-29858-367
862-34776-424
980-39899-483
10100-449125-541
11123-497152-593
12146-541178-636
13168-576200-664
14187-599214-673
15201-609218-659
16209-602208-619
17207-576185-551

Read on the Mayo Clinic Laboratories Extended Catalog (testcatalog.org), because mayocliniclabs.com blocks automated access. Mayo's own in-house IGF-1 test (IGF1S) is no longer orderable; FIGF1 is its recommended replacement. Z-score reference: -2.0 to +2.0 SD.

Labcorp gives separate adult ranges for men and women; Mayo FIGF1 gives one adult range for both sexes. For children, Mayo also reports Tanner-stage ranges on the lab report.

Units: results are reported in ng/mL. To convert to nmol/L, multiply by 0.131. [1]

Sources: [3] [10] [11]

Is there an "optimal" range?

Some clinics market an "optimal" IGF-1 level. No guideline sets one for healthy people, and the studies behind the different positions are mostly observational.

The middle of the range carries the lowest risk

120-160 ng/mL had the lowest all-cause mortality in one meta-analysis

Meta-analyses of population studies (Burgers 2011: 12 studies, 14,906 people; Rahmani 2022: 19 studies, 30,876 people) and the EPIC-Heidelberg cohort (7,461 people)

Both low and high IGF-1 were linked to higher death rates. Compared with the middle, the hazard ratio was 1.27 for low and 1.18 for high IGF-1 in Burgers, and 1.33 and 1.23 in Rahmani. EPIC-Heidelberg found the same U shape over 17.5 years.

Sources: [12] [13] [14]

Higher is not better, especially later in life

UK Biobank analyses (Zhang 2021: 440,185 people; Watts 2021: 199,698 men) and a pooled analysis of 17 breast-cancer studies

Younger people with high IGF-1 had less disease, while older people with high IGF-1 had more. Higher IGF-1 was linked to more prostate cancer (hazard ratio 1.09 per 5 nmol/L) and more breast cancer (odds ratio 1.28, top vs bottom fifth).

Sources: [15] [16] [17]

Lower may protect against cancer and diabetes

A 22-year study of people in Ecuador with growth hormone receptor deficiency (Laron syndrome), and protein-restriction research

People with lifelong very low IGF-1 had one nonfatal cancer and no diabetes, versus 17% cancer and 5% diabetes in control subjects. Researchers have suggested cutting protein intake to lower IGF-1, but this is not an established treatment.

Sources: [18] [19]

During treatment, keep it inside the normal range for age

Within the age-adjusted range; the tesamorelin label suggests stopping if it stays above +3 SDS

Growth hormone replacement practice in adults, and the FDA label for tesamorelin (Egrifta SV)

GH doses are adjusted to keep IGF-1 within target limits and to avoid "iatrogenic biochemical acromegaly" (too much GH effect caused by treatment). The Egrifta SV label says to monitor IGF-1 and to consider stopping with persistent elevations (e.g., above +3 SDS).

Sources: [20] [21]

What raises it

FactorHowHow much
Growth hormone (excess or treatment)HormoneGH switches on the IGF-1 gene in the liver through STAT5b.Active acromegaly: about 5 times the normal mean in the first radioimmunoassay study. GH injections raised levels within 72 hours in 8 of 10 GH-deficient children. [22] [6]
Childhood and pubertyPhysiologyLevels are lowest at birth, rise through childhood and peak in the teens, which is why ranges are set by age.Labcorp's upper limit for 15-year-old boys (760 ng/mL) is more than twice that for men aged 21-25 (353 ng/mL). [22] [3]
PregnancyPhysiologyA growth hormone made by the placenta takes over from the mother's pituitary GH, and maternal IGF-1 rises steadily through pregnancy.No published magnitude [23]
TestosteroneHormoneIn 11 healthy men, testosterone enanthate (300 mg a week for 6 weeks) raised IGF-I; nandrolone did not.No published magnitude [24]
Milk and dairyNutritionIn randomized trials, people assigned to drink more milk had higher IGF-I than controls.+13.8 ng/mL (95% CI 6.1-21.5), meta-analysis of randomized trials [25]
Insulin reaching the liverHormonePortal insulin sets how many GH receptors the liver makes. When it is high (obesity, Cushing's syndrome, glucocorticoids), IGF-1 can run high relative to GH.No published magnitude [7]
A single exercise sessionLifestyleTotal IGF-1 rises after endurance or resistance exercise; free IGF-1 does not change.Effect size 0.81 (endurance) and 0.46 (resistance) on total IGF-1, meta-analysis of 21 studies [26]
GH-releasing peptidesPeptideGHRH analogs and GH secretagogues make the pituitary release more GH. See the peptide table below for each one.Up to +84% vs +17% on placebo (MK-677, 6 months) [27]

What lowers it

FactorHowHow much
Growth hormone deficiencyConditionWithout enough GH, the liver makes little IGF-1. A normal result does not rule GH deficiency out.All 19 GH-deficient children in the first radioimmunoassay study were below 0.20 U/mL, against an adult mean of 1.50 U/mL. [22] [20]
AgingPhysiologyGH and IGF-I both decline with age.Labcorp, men: 109-353 ng/mL at ages 21-25 vs 45-207 ng/mL at ages 76-80. [28] [3]
Low protein intakeNutritionProtein intake is a key driver of IGF-1 in humans. Severe calorie restriction without malnutrition did not lower it.Cutting protein from 1.67 to 0.95 g/kg/day for 3 weeks lowered IGF-1 from 194 to 152 ng/mL (6 people) [19]
Malnutrition and anorexia nervosaConditionPoor nutrition lowers IGF-1 even when GH is normal or high, because the liver becomes resistant to GH.No published magnitude [3] [7]
Type 1 diabetesConditionLow insulin reaching the liver makes it less sensitive to GH, so GH can run high while IGF-1 runs low.No published magnitude [7]
Estrogen taken by mouthMedicationIn a 6-month randomized trial of postmenopausal women, oral estradiol lowered IGF-1 compared with placebo and with skin-patch estradiol; the patch had no effect.No published magnitude [29]
Acute or critical illnessConditionCritical illness makes the body resistant to GH, which lowers IGF-1.Within 24 hours of a heart attack: 115 vs 615 ng/mL in matched controls (23 patients); levels recovered to 460 ng/mL a year later [30] [31]
Chronic kidney diseaseConditionKidney failure causes GH resistance and raises IGF binding proteins, which leaves less free IGF-1.No published magnitude [32]
CirrhosisConditionOnce cirrhosis is established, IGF-1 deficiency is common whatever the cause of the liver damage.No published magnitude [33]
Growth hormone receptor defects (Laron syndrome)ConditionMutations in the GH receptor gene cause severe GH receptor and IGF-1 deficiency.No published magnitude [18]
Somatostatin analogsMedicationOctreotide, lanreotide and pasireotide block GH release. See the peptide table below.IGF-1 normalized in 43% of acromegaly patients after 48 weeks of lanreotide [34]

Peptides that affect IGF-1

How each peptide in our library has been shown to affect IGF-1, strongest evidence first. "No clear effect" means IGF-1 was measured and did not change. "Mechanism only" means no study has measured IGF-1 for that peptide itself.

PeptideEffect on IGF-1Size of effectEvidence
AnamorelinRaises+51.16 ng/mL vs placebo (meta-analysis of 5 trials, 1,331 people with cancer)Studied for cancer-related weight and muscle loss (cachexia). [35]Human trials
CapromorelinRaisesSustained, dose-related rise in every dosing group (395 adults aged 65-84)Oral GH secretagogue. Lean mass rose 1.4 vs 0.3 kg at 6 months. In beagles, 4 days of dosing doubled plasma IGF-1. [36] [37]Human trials
CerebrolysinRaisesTotal IGF-I rose with the 60 mL dose, and dissociable IGF-I rose with dose vs placebo (207 people with Alzheimer's, measured at 24 weeks)Given by IV infusion for 12 weeks in one placebo-controlled trial. [38]Human trials
CJC-1295RaisesIGF-I up 1.5- to 3-fold for 9-11 days after one injection; above baseline for up to 28 days with repeated dosesLong-acting GHRH analog (with DAC). Two placebo-controlled dose trials in healthy adults aged 21-61. [39]Human trials
GHRH (1-29)RaisesIGF-I rose within 2 weeks of nightly injections (10 µg/kg), stayed up for 12 weeks and drifted back toward baseline by 16 weeksTested as the analog [Nle27]GHRH(1-29) in 19 adults aged 55-71, after 4 weeks of placebo injections. [40]Human trials
GHRP-2RaisesBrought low IGF-I back to normal in men with prolonged critical illness (5-day IV infusion, 1 µg/kg/h)Studied in prolonged critical illness, where IGF-1 is suppressed, so this shows recovery to normal rather than a rise above it. [41]Human trials
IGF-1 (Insulin-Like Growth Factor 1)Raises6-day IV infusion (about 30 mg/day) in two healthy adults raised complex-bound IGF-I from 92 to 389 µg/L and free IGF-I from 15 to 80 µg/LRecombinant IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency in children. Its label notes tumors were seen more often at doses that pushed serum IGF-1 above the normal range for age and sex. [5] [8]Human trials
LeptinRaisesIGF-1 SDS rose by 1.63 after 12 months of metreleptin (8 children with congenital leptin deficiency)Studied only in children who lack leptin from birth; their IGF-1 was low before treatment. [42]Human trials
MK-677 (Ibutamoren)Raises+84% vs +17% on placebo over 6 months (25 mg/day, 161 adults aged 65+ after hip fracture); about +40% in 8 weeks in obese menOral GH secretagogue (ibutamoren). In a 12-month Alzheimer's trial it raised IGF-1 but did not slow the disease. [27] [43] [44]Human trials
SermorelinRaises1 mg twice daily for 14 days brought IGF-I in old men up to young-men levels; 2 mg once nightly for 6 weeks did not change itSermorelin is GHRH(1-29). In these two small trials of healthy older men, how often it was given decided whether IGF-1 moved. [28] [45]Human trials
TesamorelinRaises+108 ng/mL vs -7 ng/mL on placebo at 26 weeks (2 mg/day, 806 adults with HIV)FDA-approved GHRH analog. In obese adults with low GH, IGF-I rose 86 vs -6 µg/L over 12 months. The Egrifta SV label says to monitor IGF-1: at 26 weeks, 47% had IGF-1 above +2 SDS and 36% above +3 SDS. [46] [47] [21]Human trials
AOD-9604No clear effectNo effect on serum IGF-1 in a meta-analysis of six randomized trials (as reported in a 2026 review)A GH fragment designed to keep GH's fat-burning signal without its growth effects. [48] [49]Human trials
GhrelinNo clear effectNo change in IGF-1 during 2-hour infusions that doubled or tripled blood ghrelin (8 healthy adults)GH rose during the infusions. These were short infusions; no longer human trial of ghrelin measuring IGF-1 was found. [50]Human trials
GHRP-6No clear effectNo change in plasma IGF-I after a single IV dose (1 µg/kg)Tested once in people with high cortisol and in healthy controls. No study of repeated GHRP-6 alone with IGF-1 measured was found; men taking it together with GHRP-2 and sermorelin saw IGF-1 rise from 159.5 to 239.0 ng/mL in a retrospective review. [51] [52]Human trials
HexarelinNo clear effectNo significant change in serum IGF-I over 16 weeks of twice-daily injections (P = 0.24)The GH response to hexarelin weakened during treatment and recovered after stopping. One-day schedules of two or three injections also left IGF-I unchanged. [53] [54]Human trials
HGH Fragment 176-191No clear effectNo meaningful IGF-1 elevation in human studies (as reported in a 2026 review)The review treats hGH 176-191 and AOD-9604 as the same peptide. [49] [48]Human trials
LanreotideLowersIGF-1 normalized in 43% (27/63) of acromegaly patients after 48 weeksSomatostatin analog (Somatuline Depot). A review reports hormone control in 35-70% of patients across studies, depending on who was treated. [34] [55]FDA label
OctreotideLowersIGF-1 normalized in 51% (45/88) of acromegaly patients on monthly Sandostatin LAR over 27-28 injectionsSomatostatin analog. In a 2025 trial of a monthly self-injected depot (CAM2029) in patients already controlled, 72.2% kept IGF-1 at or below the upper limit vs 37.5% on placebo. [56] [57]FDA label
PasireotideLowersIGF-1 normalized in 38.6% vs 23.6% on an active comparator at 12 months (acromegaly, no prior drug treatment)Second-generation somatostatin analog (Signifor LAR). In patients not controlled on older analogs, 15.4-20.0% reached combined GH and IGF-1 control at 6 months. [58]FDA label
IGF-1 LR3LowersThe animals' own plasma IGF-I fell during infusion: guinea pigs (7 days) and pigs (4 days)An IGF-1 analog that binds poorly to IGF binding proteins. In pigs, mean GH fell 23%, which the authors suggest may explain the drop. Anti-doping labs detect LR3 with mass spectrometry; in rats it was no longer detected after 4 hours. [59] [60] [61]Animal studies
IpamorelinNo clear effectNo change in total IGF-I (adult female rats, 15 days)A selective GH secretagogue. Bone growth increased in the same rats. No human IGF-1 data have been published. [62]Animal studies
GHRH (1-44)RaisesNo published magnitude for native GHRH in the studies reviewed (mechanism only)The body's own GH-releasing hormone. Its analogs raise IGF-1 in trials (see Tesamorelin and Sermorelin); their figures are not shown here because they are different molecules. [46] [28]Mechanism only
Mod GRF 1-29RaisesNo published magnitude: no study has measured IGF-1 after Mod GRF 1-29 (mechanism only)A GHRH(1-29) analog without DAC. Related GHRH(1-29) peptides raise IGF-1 in people: sermorelin given twice daily restored IGF-1 in older men, and CJC-1295 (the version with DAC) raised it 1.5- to 3-fold. [28] [39]Mechanism only
SomatostatinLowersNo published magnitude for native somatostatin given systemically (mechanism only)The body's own GH-blocking hormone. In rat liver cells it also blocked GH-driven IGF-1 production directly. The measured IGF-1 reductions in people come from its long-acting analogs (octreotide, lanreotide, pasireotide). [63]Mechanism only

What high or low results can mean

A high result

A result above the range for your age and sex at your lab usually prompts a check for growth hormone excess.

  • Acromegaly (a GH-secreting pituitary tumor)
  • Taking GH or a GH-releasing peptide (see the peptide table)
  • Puberty and pregnancy, which raise it naturally
  • Comparing against another lab's range

Next step: Discuss it with a clinician. Acromegaly is assessed with IGF-1 together with growth hormone, including GH measured after an oral glucose tolerance test.

Sources: [64] [22] [23]

A low result

A low result can point to growth hormone deficiency, but it is not specific, and a normal result does not rule GH deficiency out.

  • Growth hormone deficiency
  • Poor nutrition or low protein intake
  • Estrogen taken by mouth
  • Acute illness, kidney disease or cirrhosis
  • Older age (check the age-specific range)

Next step: Discuss it with a clinician. IGF-1 alone has poor accuracy for GH deficiency, which is usually confirmed with a GH stimulation test.

Sources: [20] [65] [66]

How the test works

SampleSerum. Labcorp asks for 0.5 mL in a red-top or gel-barrier tube and rejects plasma; Mayo FIGF1 asks for 0.5 mL of serum.
FastingNeither Labcorp nor Mayo lists fasting. Labcorp asks you to stop high-dose biotin at least 72 hours before the draw, because biotin can interfere with its assay.
TimingSerum IGF-1 was stable for at least 72 hours whatever the storage temperature, and for 7 days refrigerated, so shipping delays rarely matter.
Lab differencesSix commercial assays tested on the same 911 healthy adults gave similar lower limits but very different upper limits, with only moderate-to-good agreement (0.38-0.70). Repeat tests on the same lab and assay if you want to compare them.
RetestingTwo draws two weeks apart in 84 healthy adults differed by -36% to +38%, and 40.5% moved to a different quartile. In older adults, a change needs to exceed about 31% (down) or 44% (up) to stand out from normal variation.
Labcorp order code010363: Insulin-like Growth Factor 1 (IGF-1)
Labcorp order code010540: Insulin-like Growth Factor-1 (IGF-1) With Z Score
Mayo Clinic Laboratories order codeFIGF1: IGF-1, LC/MS (performed by Quest Diagnostics)
LOINC codes
  • 2484-4: Insulin-like growth factor-I [Mass/volume] in Serum or Plasma
  • 73561-3: Insulin-like growth factor-I [Z-score] in Serum or Plasma (Z-score result on Labcorp 010540 and Mayo FIGF1)
  • 29775-4: Insulin-like growth factor-I [Moles/volume] in Serum or Plasma (nmol/L results)
LOINC 2484-4 on loinc.org

Sources: [3] [67] [10] [68] [69] [11] [70] [71]

History

The hormone measured by this test went through four names in 30 years. Lab reports still use two of them.

  1. 1957Salmon and Daughaday describe a hormonally controlled serum factor that stimulates sulfate uptake by cartilage, later called "sulfation factor". [72] [73]
  2. 1963Froesch and colleagues describe insulin-like activity in serum that insulin antibodies cannot suppress, later known as NSILA (non-suppressible insulin-like activity). [74] [75]
  3. 1972Daughaday, Hall, Raben, Salmon, Van den Brande and Van Wyk propose "somatomedin" as the name for sulfation factor. [73]
  4. 1976Rinderknecht and Humbel isolate two forms of NSILA from human plasma, NSILA I and II. [75]
  5. 1977Furlanetto and colleagues publish the first radioimmunoassay for somatomedin-C, finding high levels in acromegaly and low levels in GH-deficient children. [22]
  6. 1978Rinderknecht and Humbel sequence "insulin-like growth factor I": 70 amino acids, molecular weight 7,649, similar to proinsulin. [1]
  7. 1980Hintz and Rinderknecht show somatomedin-C and IGF-I are indistinguishable by immunoassay; in 1983 Klapper and colleagues confirm by sequencing that they are the same peptide. [76] [77]
  8. 1987The original investigators publish a joint note on the nomenclature of the somatomedins and insulin-like growth factors. [78]
  9. 2005FDA approves recombinant IGF-1 (mecasermin, Increlex) for children with severe primary IGF-1 deficiency. [8]
  10. 2009The WHO establishes preparation 02/254 as the first International Standard for IGF-1 immunoassays (8.50 µg per ampoule). [79]
  11. 2011A consensus statement from growth hormone, IGF and laboratory medicine societies calls for major improvements in IGF-I assay performance and comparability. [80]

FAQ

Do I need to fast before an IGF-1 test?

Neither Labcorp nor Mayo lists fasting as a requirement for its IGF-1 test. Labcorp does ask you to stop high-dose biotin supplements at least 72 hours before the draw, because biotin can interfere with the assay.

Sources: [3] [67] [10]

Why do different labs give different normal ranges?

Each assay reads the same blood differently. When six commercial assays were run on the same 911 healthy adults, their lower limits were similar but their upper limits varied markedly. Labcorp's range for men aged 21-25 is 109-353 ng/mL; Mayo's LC/MS range for adults aged 20-24 is 83-456 ng/mL.

Sources: [11] [3] [10]

What is a normal IGF-1 level for my age?

It depends on your age, sex and lab, so use the range printed on your report. Levels peak in the teens and fall through adulthood: Labcorp's range for women aged 26-30 is 91-308 ng/mL, and for women aged 66-70 it is 52-196 ng/mL.

Sources: [3]

Why is my IGF-1 low?

Common reasons include older age, low protein intake or poor nutrition, estrogen taken by mouth, acute illness, kidney disease and cirrhosis. Growth hormone deficiency is another cause, but a low result does not prove it and a normal result does not rule it out, so a clinician may order a GH stimulation test.

Sources: [19] [29] [30] [20] [66]

Is a high IGF-1 bad?

A result above your lab's age range is worth checking with a clinician, because acromegaly is one cause. In population studies, IGF-1 in the top range was linked to higher mortality (hazard ratio 1.18 vs the middle) and to more breast and prostate cancer. These studies show links, not proof that IGF-1 causes the disease.

Sources: [64] [12] [17] [16]

Can peptides raise IGF-1?

Some can. In trials, MK-677 (Ibutamoren) raised IGF-I by 84% over 6 months, CJC-1295 raised it 1.5- to 3-fold after one injection, and Tesamorelin raised it by 108 ng/mL. Others did not: Hexarelin left IGF-I unchanged over 16 weeks. The table above lists every peptide we cover.

Sources: [27] [39] [46] [53]

Does IGF-1 cause cancer?

It is not proven, but the evidence leans that way for prostate cancer: a UK Biobank study found higher IGF-1 linked to more prostate cancer, and a genetic (Mendelian randomization) analysis supported a causal role. At the other extreme, people with lifelong very low IGF-1 from GH receptor deficiency had almost no cancer over 22 years.

Sources: [16] [18]

How is IGF-1 different from a growth hormone test?

IGF-1 is made in response to growth hormone and is mostly held in a complex that lasts 12-15 hours in the blood, so one sample gives a usable reading. GH itself is usually judged with dynamic tests: a GH suppression test (oral glucose) for acromegaly, or a stimulation test for deficiency.

Sources: [5] [64] [66]

How much can IGF-1 change between two tests?

More than many people expect. In 84 healthy adults tested two weeks apart, individual results differed by up to about 36-38%, and 40.5% moved to a different quartile. In older adults, a fall of about 31% or a rise of about 44% is needed before a change stands out from normal variation.

Sources: [70] [71]

Can diet change IGF-1?

Protein matters most. Cutting protein from 1.67 to 0.95 g/kg a day for 3 weeks lowered IGF-1 from 194 to 152 ng/mL, while long-term calorie restriction without malnutrition did not lower it. In randomized trials, drinking more milk raised IGF-I by about 13.8 ng/mL.

Sources: [19] [25]

Does exercise affect IGF-1?

A single session raises total IGF-1 a little, more after endurance exercise (effect size 0.81) than resistance exercise (0.46). Free IGF-1 did not change.

Sources: [26]

What is an IGF-1 Z-score?

It shows how far your result is from the average for your age and sex, in standard deviations. Labcorp (010540) and Mayo (FIGF1) report one, and Mayo treats -2.0 to +2.0 as the reference range. The tesamorelin label uses the same scale: it suggests considering stopping treatment if IGF-1 stays above +3.

Sources: [67] [10] [21]

Do birth control pills or hormone therapy affect the result?

Estrogen taken by mouth can. In a 6-month randomized trial in postmenopausal women, oral estradiol lowered IGF-1 compared with placebo, while estradiol through the skin had no effect.

Sources: [29]

References

  1. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253(8):2769-76. PMID 632300
  2. Sjögren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A. 1999;96(12):7088-92. PMID 10359843
  3. Labcorp. Test 010363: Insulin-like Growth Factor 1 (IGF-1). Reference intervals, specimen requirements, methodology and LOINC map. labcorp.com/tests/010363/insulin-like-growth-factor-1-igf-1
  4. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999;96(13):7324-9. PMID 10377413
  5. Guler HP, Zapf J, Schmid C, et al. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh). 1989;121(6):753-8. PMID 2558477
  6. Chia DJ, Varco-Merth B, Rotwein P. Dispersed Chromosomal Stat5b-binding elements mediate growth hormone-activated insulin-like growth factor-I gene transcription. J Biol Chem. 2010;285(23):17636-47. PMID 20378540
  7. Yuen KCJ, Hjortebjerg R, Ganeshalingam AA, et al. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin. Front Endocrinol (Lausanne). 2024;15:1456195. PMID 39665021
  8. INCRELEX (mecasermin) injection, prescribing information. DailyMed (initial US approval 2005). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce
  9. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 1994;42(4-5):140-4. PMID 7532612
  10. Mayo Clinic Laboratories. Test ID FIGF1: IGF-1, LC/MS (performing laboratory: Quest Diagnostics Nichols Institute). Mayo Clinic Laboratories Extended Catalog (mirror of mayocliniclabs.com/test-catalog/overview/75932). testcatalog.org/show/FIGF1
  11. Chanson P, Arnoux A, Mavromati M, et al. Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays. J Clin Endocrinol Metab. 2016;101(9):3450-8. PMID 27167056
  12. Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab. 2011;96(9):2912-20. PMID 21795450
  13. Rahmani J, Montesanto A, Giovannucci E, et al. Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis. Aging Cell. 2022;21(2):e13540. PMID 35048526
  14. Mukama T, Srour B, Johnson T, et al. IGF-1 and Risk of Morbidity and Mortality From Cancer, Cardiovascular Diseases, and All Causes in EPIC-Heidelberg. J Clin Endocrinol Metab. 2023;108(10):e1092-e1105. PMID 37066827
  15. Zhang WB, Ye K, Barzilai N, et al. The antagonistic pleiotropy of insulin-like growth factor 1. Aging Cell. 2021;20(9):e13443. PMID 34363732
  16. Watts EL, Fensom GK, Smith Byrne K, et al. Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank. Int J Cancer. 2021;148(9):2274-2288. PMID 33252839
  17. Key TJ, Appleby PN, Reeves GK, et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530-42. PMID 20472501
  18. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13. PMID 21325617
  19. Fontana L, Weiss EP, Villareal DT, et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008;7(5):681-7. PMID 18843793
  20. Mukherjee A, Shalet SM. The value of IGF1 estimation in adults with GH deficiency. Eur J Endocrinol. 2009;161 Suppl 1:S33-9. PMID 19684059
  21. EGRIFTA SV (tesamorelin) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
  22. Furlanetto RW, Underwood LE, Van Wyk JJ, et al. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest. 1977;60(3):648-57. PMID 893668
  23. Caufriez A, Frankenne F, Hennen G, et al. Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol. 1993;265(4 Pt 1):E572-7. PMID 8238332
  24. Hobbs CJ, Plymate SR, Rosen CJ, et al. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab. 1993;77(3):776-9. PMID 7690364
  25. Qin LQ, He K, Xu JY. Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review. Int J Food Sci Nutr. 2009;60 Suppl 7:330-40. PMID 19746296
  26. de Alcantara Borba D, da Silva Alves E, Rosa JPP, et al. Can IGF-1 Serum Levels Really be Changed by Acute Physical Exercise? A Systematic Review and Meta-Analysis. J Phys Act Health. 2020;17(5):575-584. PMID 32259791
  27. Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004;52(4):516-23. PMID 15066065
  28. Corpas E, Harman SM, Piñeyro MA, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5. PMID 1379256
  29. Sonnet E, Lacut K, Roudaut N, et al. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf). 2007;66(5):626-31. PMID 17492948
  30. Crown AL, Holly JM. The insulin-like growth factor system in critical illness: pathophysiology and therapeutic potential. Clin Nutr. 1995;14(6):321-8. PMID 16843952
  31. Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol. 2001;38(1):26-32. PMID 11451284
  32. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol. 2008;23(1):41-8. PMID 17676425
  33. de la Garza RG, Morales-Garza LA, Martin-Estal I, et al. Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment. J Clin Med Res. 2017;9(4):233-247. PMID 28270882
  34. SOMATULINE DEPOT (lanreotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d
  35. Rezaei S, de Oliveira LC, Ghanavati M, et al. The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials. J Oncol Pharm Pract. 2023;29(7):1725-1735. PMID 37525932
  36. White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94(4):1198-206. PMID 19174493
  37. Lanz TA, Salatto CT, Semproni AR, et al. Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. Biochem Pharmacol. 2008;75(5):1093-103. PMID 18076866
  38. Alvarez XA, Sampedro C, Cacabelos R, et al. Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. Int J Neuropsychopharmacol. 2009;12(7):867-72. PMID 19531281
  39. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683
  40. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. PMID 9141536
  41. Van den Berghe G, Baxter RC, Weekers F, et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf). 2002;56(5):655-69. PMID 12030918
  42. Beghini M, Brandt S, Körber I, et al. Serum IGF1 and linear growth in children with congenital leptin deficiency before and after leptin substitution. Int J Obes (Lond). 2021;45(7):1448-1456. PMID 34002033
  43. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9. PMID 9467542
  44. Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-8. PMID 19015485
  45. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PMID 9005976
  46. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PMID 20554713
  47. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-79. PMID 23015655
  48. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMID 41490200
  49. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PMID 42395176
  50. Lucidi P, Murdolo G, Di Loreto C, et al. Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis. 2005;15(6):410-7. PMID 16314227
  51. Borges MH, DiNinno FB, Lengyel AM. Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism. Clin Endocrinol (Oxf). 1997;46(6):713-8. PMID 9274702
  52. Sigalos JT, Pastuszak AW, Allison A, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017;11(6):1752-1757. PMID 28830317
  53. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-9. PMID 9589671
  54. Maccario M, Veldhuis JD, Broglio F, et al. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol. 2002;146(3):310-8. PMID 11888836
  55. Castinetti F, Saveanu A, Morange I, et al. Lanreotide for the treatment of acromegaly. Adv Ther. 2009;26(6):600-12. PMID 19533047
  56. SANDOSTATIN LAR DEPOT (octreotide acetate) for injectable suspension, prescribing information. DailyMed (initial US approval of octreotide 1988). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0b7fe9e-7000-4b79-ba3b-291ce92c14f9
  57. Ferone D, Freda P, Katznelson L, et al. Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1. J Clin Endocrinol Metab. 2025;110(6):1729-1739. PMID 39378125
  58. SIGNIFOR LAR (pasireotide) for injectable suspension, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0aad470-3f38-af97-e053-2995a90a383a
  59. Conlon MA, Tomas FM, Owens PC, et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-53. PMID 7561636
  60. Dunaiski V, Dunshea FR, Walton PE, et al. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol. 1997;155(3):559-65. PMID 9488001
  61. Mongongu C, Coudoré F, Domergue V, et al. Detection of LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Test Anal. 2021;13(7):1256-1269. PMID 33587816
  62. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. PMID 10373343
  63. Murray RD, Kim K, Ren SG, et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114(3):349-56. PMID 15286801
  64. Akirov A, Masri-Iraqi H, Dotan I, et al. The Biochemical Diagnosis of Acromegaly. J Clin Med. 2021;10(5). PMID 33803429
  65. Ibba A, Corrias F, Guzzetti C, et al. IGF1 for the diagnosis of growth hormone deficiency in children and adolescents: a reappraisal. Endocr Connect. 2020;9(11):1095-1102. PMID 33112822
  66. Garcia JM, Biller BMK, Korbonits M, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018;103(8):3083-3093. PMID 29860473
  67. Labcorp. Test 010540: Insulin-like Growth Factor-1 (IGF-1) With Z Score. LOINC map and special instructions. labcorp.com/tests/010540/insulin-like-growth-factor-1-igf-1-with-z-score
  68. LOINC 2484-4: Insulin-like growth factor-I [Mass/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/2484-4
  69. Louw JC, George JA, Khoza SP, et al. Short- and medium-term pre-analytical stability of human serum insulin-like growth factor-1. Clin Chem Lab Med. 2026;64(3):630-639. PMID 41167200
  70. Milani D, Carmichael JD, Welkowitz J, et al. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab. 2004;89(5):2271-4. PMID 15126552
  71. Tausendfreund O, Reif H, Bidlingmaier M, et al. Estimation of the biological variation of IGF-I in multimorbid geriatric patients and its clinical implications. Pituitary. 2025;28(3):59. PMID 40348938
  72. SALMON WD, DAUGHADAY WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957;49(6):825-36. PMID 13429201
  73. Daughaday WH, Hall K, Raben MS, et al. Somatomedin: proposed designation for sulphation factor. Nature. 1972;235(5333):107. PMID 4550398
  74. FROESCH ER, BUERGI H, RAMSEIER EB, et al. ANTIBODY-SUPPRESSIBLE AND NONSUPPRESSIBLE INSULIN-LIKE ACTIVITIES IN HUMAN SERUM AND THEIR PHYSIOLOGIC SIGNIFICANCE. AN INSULIN ASSAY WITH ADIPOSE TISSUE OF INCREASED PRECISION AND SPECIFICITY. J Clin Invest. 1963;42(11):1816-34. PMID 14083170
  75. Rinderknecht E, Humbel RE. Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc Natl Acad Sci U S A. 1976;73(7):2365-9. PMID 1065887
  76. Hintz RL, Rinderknecht E. Somatomedin-C shares the carboxy-terminal antigenic determinants with insulin-like growth factor-I. J Clin Endocrinol Metab. 1980;51(3):672-3. PMID 6157699
  77. Klapper DG, Svoboda ME, Van Wyk JJ. Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I. Endocrinology. 1983;112(6):2215-7. PMID 6343062
  78. Daughaday WH, Hall K, Salmon WD, et al. On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab. 1987;65(5):1075-6. PMID 3667879
  79. Burns C, Rigsby P, Moore M, et al. The First International Standard For Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res. 2009;19(5):457-62. PMID 19303800
  80. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57(4):555-9. PMID 21285256

Educational information, not medical advice. Lab ranges and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.